Already a Bloomberg.com user?
Sign in with the same account.
Don't have an account?
Help! I can't access my account.
Merck KGaA, the German maker of the cancer drug Erbitux, increased earnings and sales forecasts for 2012 after currency shifts and demand for medicines helped second-quarter profit jump 14 percent.
On Air Now
On the Move with Rishaad Salamat
Max 250 characters
©2013 Bloomberg L.P. All Rights Reserved. Made in NYC